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Introduction
Aberrant regulation of the intracellular signaling pathways that 
underlie normal hematopoietic stem cell (HSC) renewal and dif-
ferentiation is one of the pathogenic hallmarks of human leukemia. 
mTOR plays an essential role in regulating HSC generation and is 
involved in leukemogenesis (1–3). mTOR is present in 2 distinct 
multiprotein complexes — mTORC1 and mTORC2 (4). Among 
the various substrates phosphorylated by mTORC1, S6 kinase 1 
(S6K1) and eukaryotic initiation factor 4E–binding (eIF4E-bind-
ing) protein 1 (4E-BP1) are perhaps the best-characterized down-
stream substrates. Given the known crosstalk between mTORC1 
and mTORC2, the specific role of the individual downstream sub-
strates of mTORC1 and mTORC2 in regulating benign and malig-
nant hematopoiesis can best be assessed by examining HSCs 
lacking the downstream components of this pathway. Here, we 
investigated the role of S6K1 in steady-state, stress, and malignant 
hematopoiesis using a mouse model of S6K1 deficiency. Our stud-
ies reveal that the self-renewal of HSCs and the leukemic potential 
of these cells are similarly dependent on S6K1 and provide mecha-
nistic insight into how loss of S6K1 may contribute to normal and 
malignant stem cell function or functions and establish S6K1 as a 
potential therapeutic target in the treatment of leukemia.
Results and Discussion
We first examined the expression of S6k1 in BM-derived frac-
tions of HSCs and progenitor cells (HSC/Ps). S6k1 is expressed 
in long-term HSCs (LT-HSCs) as well as in various progenitor 
populations (Figure 1A). However, the expression of S6k1 is sig-
nificantly higher in granulocyte-macrophage progenitors (GMPs) 
and megakaryocyte-erythroid progenitors (MEPs) and signifi-
cantly less in mature myeloid cells relative to LT-HSCs (Figure 
1A). To address the role of S6K1 in steady-state hematopoiesis, 
we examined the effect of S6K1 deficiency on BM-derived HSC/
Ps. S6K1 deficiency resulted in a significant reduction in BM 
mononuclear cells (MNCs) (Figure 1B). Although S6K1 defi-
ciency does not affect HSC frequency, a decrease in the absolute 
number of LT-HSCs (CD150+CD48–LSK) and MPPs (CD150–
CD48–LSK) was observed (Figure 1C and Supplemental Figure 1, 
A and B; supplemental material available online with this article; 
doi:10.1172/JCI84565DS1). The frequency of MPPs in S6k1–/– BM 
was reduced, while the frequency of hematopoietic progenitor 
cells 1 (HPC1) (CD150–CD48+LSK) and HPC2 (CD150+CD48–
LSK) was increased (Supplemental Figure 1, A–C). The frequency 
of GMPs was increased in S6k1–/– mice, while the frequency of 
MEPs was reduced (Figure 1D and Supplemental Figure 1D). The 
absolute number of common myeloid progenitors (CMPs) and 
MEPs was significantly reduced following S6K1 deficiency (Fig-
ure 1D). The frequency of myeloid cells in the BM of S6k1–/– mice 
was also elevated, while the frequency and absolute number of B 
cells were reduced (Supplemental Figure 1, E–G). The changes in 
BM cellularity as well as in the GMP and B cell fractions observed 
in S6k1–/– mice are similar to those reported in mTORC1-deficient 
mice (2, 3). Given that mTORC1 regulates quiescence in HSCs (5), 
we analyzed the impact of S6K1 deficiency on HSC quiescence 
by assessing the level of expression of Ki-67, a marker absent in 
quiescent cells. S6K1-deficient LT-HSCs showed reduced fre-
quency of Ki-67–negative cells, suggesting decreased quiescence 
in LT-HSCs (Figure 1E), which was associated with a reduction in 
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vived beyond 4 weeks after injection. In contrast, all S6k1–/– mice 
died by day 18 after the first injection of 5-FU (Figure 2D). To 
determine whether the susceptibility of S6k1–/– mice to repeat-
ed stress is due to an HSC-specific defect, we transplanted WT 
mice with either WT or S6k1–/– HSC/Ps and treated the recipients 
with weekly doses of 5-FU. WT mice transplanted with S6k1–/– 
HSC/Ps showed significantly reduced median survival compared 
with WT mice transplanted with WT HSC/Ps (Figure 2E). 5-FU–
treated HSC/Ps also showed reduced engraftment following S6K1 
deficiency at increased cell dilution, but not in lower dilution (Fig-
ure 2F and Supplemental Figure 2E). Thus, although S6K1 defi-
ciency causes an increase in HSC frequency upon 5-FU adminis-
tration, it also results in the loss of quiescence and resultant failure 
in HSC regeneration following repeated myelosuppressive stress. 
Overall, our results show that S6K1 regulates quiescence follow-
ing regeneration of HSCs after myeloablative stress and that defi-
ciency of S6K1 renders HSCs susceptible to repeated stress and 
reduced engraftment potential.
As S6K1 deficiency results in reduced number and quiescence 
of phenotypically defined LT-HSCs, we assessed whether S6K1 
regulates the function of HSCs. We performed competitive trans-
plants using WT or S6k1–/– BM MNCs along with competitor cells. 
Initially, we observed a defect in the short-term engraftment in 
the expression of cyclin-dependent kinase inhibitor 1A (Cdkn1a) 
encoding p21 (Figure 1F).
Given the impaired quiescence and the associated decline in 
the expression of Cdkn1a due to S6K1 deficiency in LT-HSCs, we 
hypothesized that under conditions of stress, reduced quiescence 
might result in enhanced HSC depletion and hematopoietic fail-
ure in S6k1–/– mice. To test this, we treated WT and S6k1–/– mice 
with a single dose of 5-fluorouracil (5-FU) to examine the recov-
ery of HSCs. The BM cellularity in S6k1–/– mice remained low only 
on the fifteenth day after 5-FU treatment compared with that in 
WT (Supplemental Figure 2A). However, the frequency of LSK 
cells in S6k1–/– mice was higher than that in WT mice on the ninth 
day after 5-FU injection (Figure 2A and Supplemental Figure 2B). 
S6K1-deficient LSK cells also demonstrated increased cycling fol-
lowing myelosuppression (Figure 2B and Supplemental Figure 
2C), which was uniquely associated with increased expression 
of cyclin G1 (Ccng1), a protein highly expressed in self-renewing 
HSCs (ref. 6, Figure 2C, and Supplemental Figure 2D). Given 
these observations, we hypothesized that S6k1–/– HSCs are likely 
to be more susceptible to repeated 5-FU stress (7). To assess this 
in detail, WT and S6k1–/– mice were subjected to weekly doses of 
5-FU. Most of the WT mice survived until the 20th day after the 
first 5-FU injection, and approximately 20% of these mice sur-
Figure 1. S6K1 regulates HSC/Ps frequencies and absolute numbers in the BM. (A) Relative expression level of S6k1 in purified BM-derived hematopoietic 
subsets as assessed by quantitative real-time reverse-transcription PCR (qRT-PCR). Data are from a representative experiment performed twice indepen-
dently in replicates of 4; mean ± SD. *P < 0.001; **P < 0.0001. (B) Total BM MNCs derived from WT and S6k1–/– mice; mean ± SEM; n = 4–5/group.  
*P < 0.002, t test. Data representative of 3 independent experiments. (C) Frequency and absolute number of LT-HSCs in the BM of WT and S6k1–/– mice.  
n = 4–5/group; mean ± SEM. *P < 0.02, t test. (D) Frequency and absolute number of hematopoietic progenitor subpopulations in bone marrow of WT and 
S6k1–/– mice; n = 4–5/group; mean ± SEM. *P < 0.02; **P < 0.005, t test. (E) Frequency of Ki-67–negative LT-HSCs in the BM of WT and S6k1–/– mice; mean 
± SEM. *P < 0.01, t test. n = 4–5 mice/group. (F) Expression levels of genes regulating quiescence in LT-HSCs of WT and S6k1–/– mice; mean ± SEM.  
*P < 0.005. Data are representative of 2 independent experiments performed in replicates of 3.
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groups in primary transplant recipients (Supplemental Figure 
3J). Consistent with our earlier observations (Figure 1F), Cdkn1a 
expression was reduced in S6K1-deficient LSK cells derived from 
the BM of secondary recipients relative to controls (Figure 3C and 
Supplemental Figure 3K). These results demonstrate that loss of 
S6K1 expression results in impaired self-renewal of HSCs, which 
is associated with reduced expression of Cdkn1a.
Previous studies have shown that the mTORC1 pathway is 
hyperactivated in acute myeloid leukemias (AMLs) bearing the 
mixed lineage leukemia (MLL) translocation and is associated with 
poor overall prognosis, including reduced survival (8, 9). Primary 
AML cells derived from patients show increased activation of S6K1 
(10). We therefore assessed the role of S6K1 in the initiation and 
self-renewal of MLL-AF9–driven leukemogenesis. We transplant-
ed WT and S6k1–/– HSC/Ps transduced with MLL-AF9 into irradi-
ated recipients. Both recipient groups showed increased wbc count 
and the presence of donor-derived myeloid cells in the PB and 
BM (Supplemental Figure 4, A–F); they also developed AML and 
had similar median survival times (Supplemental Figure 4G). The 
frequency and quiescence levels of leukemia stem cell–enriched 
(LSC-enriched) fractions were also similar in the splenocytes of 
primary recipients (Supplemental Figure 5, A–C, and ref. 11). To 
recipient mice transplanted with S6k1–/– MNCs; however, the dif-
ference did not persist long term (Supplemental Figure 3, A and 
B). In contrast, following secondary transplantation, S6k1–/– MNCs 
showed a persistent reduction in the engraftment relative to WT 
controls (Supplemental Figure 3, C and D). To assess whether the 
self-renewal defect was HSC specific, we performed competitive 
transplants using sorted LT-HSCs from WT and S6k1–/– mice. In 
the primary recipients, there was no difference in the engraftment 
of either WT or S6k1–/– donor-derived cells (Supplemental Figure 
3, E and F). There was also no difference in the differentiation of 
myeloid cells, B cells, or T cells at 24 weeks after transplantation 
between 2 groups (Supplemental Figure 3G). However, follow-
ing secondary transplant with cells derived from the BM of pri-
mary recipients, S6k1–/– donor cells demonstrated a significantly 
reduced engraftment in the peripheral blood (PB) of secondary 
recipients (Figure 3A and Supplemental Figure 3H). We further 
performed tertiary transplant with cells derived from the BM of 
secondary recipients. Recipients of S6k1–/– HSCs demonstrated 
reduced engraftment in the PB of tertiary recipients (Figure 3B 
and Supplemental Figure 3I). The engraftment of S6k1–/– donor 
cells was significantly reduced in the BM of secondary recipients, 
while there was no difference in the engraftment between the 2 
Figure 2. S6K1 regulates quiescence of HSCs following regeneration from myeloablative stress. (A) BM LSK frequency in WT and S6k1–/– mice following 
a single dose of 5-FU; mean ± SEM. *P < 0.03, t test. n = 8–18/group. (B) Quantitative representation of BrdU+ LSK cells in the BM of WT and S6k1–/– mice 
on the ninth day after 5-FU treatment; mean ± SEM. *P < 0.05, t test. n = 3/group. Data are representative of 2 independent experiments. (C) Expression 
levels of Ccng1 in BM LSK cells of WT and S6k1–/– mice on ninth day after 5-FU treatment. Data are from a representative experiment performed twice 
independently. Experiments performed in quadruplicates; mean ± SD. *P < 0.01. (D) Kaplan-Meier survival curve of WT and S6k1–/– mice treated with 
weekly doses of 5-FU. *P < 0.001. n = 11–15/group. (E) Kaplan-Meier survival curve of WT mice transplanted with WT and S6k1–/– HSC/Ps and treated with 
weekly doses of 5-FU. *P < 0.007. n = 10/group. (F) WT and S6k1–/– mice were treated with a single dose of 5-FU. After 6 days, MNCs from treated mice 
were transplanted into lethally irradiated recipients at a dilution of 1:8. Quantitative representation of donor-derived cells in PB of recipients is shown; 
mean ± SEM. n = 3/group. *P < 0.05, 1-way ANOVA.
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phorylation of AKT and 4E-BP1 was reduced in S6K1-deficient 
cells expressing MLL-AF9 compared with control (Figure 3F; see 
complete unedited blots in the supplemental material). To deter-
mine whether inhibition of S6K1 activity influences the growth and 
propagation of human AML cells (MA9-3) (12), we used a specific 
inhibitor of S6K1 activity, PF-4708671 (13). MA9-3 cells showed a 
significant reduction in growth with increasing concentrations of 
PF-4708671 (Supplemental Figure 7C). Inhibition of S6K1 activity 
also caused reduced phosphorylation of 4E-BP1 and mTOR (Fig-
ure 3G; see complete unedited blots in the supplemental material), 
a common component of mTORC1 and mTORC2, in these cells. 
Moreover, NOD/SCID mice transplanted with PF-4708671–treat-
ed MA9-3 cells showed increased median survival compared with 
vehicle-treated cells (Figure 3H) Thus, inhibition of S6K1 activity 
resulted in reduced growth of MLL-AF9–bearing human AML cells 
both in vivo and in vitro.
Our studies reveal that the self-renewal of HSCs and leukemic 
potential of these cells are similarly dependent on S6K1. Further-
more, loss of S6K1 in HSCs increases the susceptibility of mice to 
repeated myelosuppresive stress. Importantly, several biochemi-
cal and functional defects observed in the HSC compartment due 
to S6K1 deficiency resemble those seen in HSCs lacking mTORC1, 
including reduced BM cellularity and prolonged survival of leuke-
mic mice. Our data also suggest that loss of quiescence in S6k1–/– 
LT-HSCs could be a result of reduced Cdkn1a levels as S6k1–/– 
determine the effect of S6K1 on the maintenance and propagation 
of leukemia, we transplanted mice with cells derived from either 
WT or S6k1–/– primary recipients who developed leukemia around 
the same time. Mice transplanted with cells from S6k1–/– primary 
recipients survived significantly longer than the cohort transplant-
ed with cells derived from WT primary recipients (Figure 3D and 
Supplemental Figure 6A). The recipients of S6k1–/– cells depicted in 
Figure 3D showed significantly reduced spleen weight compared 
with WT controls (Supplemental Figure 6B). In the same group of 
mice, the LSC-enriched fraction showed significantly increased 
quiescence in S6k1–/– AML cells compared with WT (Figure 3E 
and Supplemental Figure 6, C–E). To further assess whether S6K1 
deficiency affects the LSC fraction, we sorted Kit+Gr1– cells from 
primary recipients and transplanted them into secondary recipi-
ents (2). Recipients of S6k1–/– Kit+Gr1– cells expressing MLL-AF9 
survived significantly longer compared with WT controls (Supple-
mental Figure 7A). Furthermore, following tertiary transplant, 
mice transplanted with cells from S6k1–/– secondary recipients from 
Figure 3D survived significantly longer than the mice transplanted 
with cells derived from WT secondary recipients (Supplemental 
Figure 7B). Thus, although S6K1 is not required for the initiation of 
leukemia, it positively regulates long-term maintenance and leuke-
mia propagation. In an effort to understand the mechanism behind 
the prolonged survival of mice bearing S6k1–/– leukemic cells, we 
examined the activation of the mTORC1/mTORC2 pathway. Phos-
Figure 3. S6K1 is a positive regulator of HSC self-renewal and prolongs the survival of leukemic mice. (A) Quantitative analysis of donor-derived chime-
rism in PB of secondary recipients of WT and S6k1–/– LT-HSCs; mean ± SEM. *P < 0.001, 1-way ANOVA. n = 9–10/group. (B) Quantitative analysis of donor-
derived chimerism in PB of tertiary transplant recipients of WT and S6k1–/– LT-HSCs; mean ± SEM. *P < 0.001, 1-way ANOVA. n = 7–10/group. (C) Expression 
of Cdkn1a in CD45.2+ LSK cells isolated from WT and S6k1–/– secondary recipients depicted in part A; mean ± SD. *P < 0.001. Experiment performed in tripli-
cate. (D) Kaplan-Meier survival curves of secondary recipients of MLL-AF9 fusion gene transduced with WT or S6k1–/– cells derived from primary recipients. 
*P < 0.001 (n = 17/group). (E) Quantitative representation of Ki-67–negative GFP+ Gr1–Mac1– Sca1–c-Kit+ cells in BM and spleen of secondary recipients (from 
part D) of WT or S6k1–/– AML cells expressing MLL-AF9; mean ± SEM. *P < 0.01, t test. n = 5 mice/group. Data representative of 2 independent experi-
ments. (F) Phosphorylation level of AKT and 4E-BP1 in WT and S6k1–/– HSC/Ps expressing MLL-AF9; n = 2. (G) Phosphorylation level of mTOR and 4E-BP1 
in MA9-3 cells following treatment with PF-4708671; n = 3. (H) Kaplan-Meier survival curves of NOD/SCID mice transplanted with MA9-3 cells treated with 
either vehicle or PF-4708671. *P < 0.05. n = 7/group.
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ANOVA followed by Tukey’s multiple comparison test. P < 0.05 was 
considered significant.
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HSCs have properties similar to those of Cdkn1a-deficient HSCs, 
including reduced quiescence, increased susceptibility to myelo-
toxic stress, and reduced self-renewal potential (14).
Propagation and relapse of leukemia have been attributed to 
the presence of LSCs within the leukemic cell population. AKT 
and mTORC1 have been shown to be activated in LSCs, rendering 
them resistant to chemotherapy, which can be reversed by inhibit-
ing AKT activation (15). Previous studies utilizing mTORC1-defi-
cient HSCs expressing MLL-AF9 have shown a similar prolonga-
tion in the survival of transplanted mice, which was associated with 
reduced 4E-BP1 and AKT phosphorylation (2). Prolonged S6K1 loss 
causes a reduction in mTOR activation, which affects the activity of 
mTORC1/ mTORC2, resulting in reduced AKT and 4E-BP1 phos-
phorylation. Previous studies have established a role of glycogen 
synthase kinase-3 (GSK-3) as a positive regulator of S6K1 activity 
(16). GSK-3 is a critical regulator of maintenance of stem cell activ-
ity in AML cells (17). Inhibition of GSK-3 activity results in down-
regulation of genes, which maintain LSCs (17). It is possible that 
S6K1 is one of the downstream substrates of GSK3 in the regulation 
of maintenance of LSCs. As inhibition of S6K1 activity prolongs the 
survival of mice bearing human AML cells, it could be used as a 
potential therapeutic target in the future to treat AML patients.
Methods
Detailed methods are described in the Supplemental Methods.
Statistics. Statistical differences between 2 groups were deter-
mined using the unpaired Student’s t test with a 2-tailed distribution. 
Differences between multiple groups were determined using 1-way 
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